A U.S. multicenter randomized trial published November 7, 2025, in JAMA reports that a conservative, indication-based approach to dialysis improved kidney function recovery among hospitalized adults with dialysis-requiring acute kidney injury (AKI) who were hemodynamically stable. The Liberation From Acute Dialysis (LIBERATE-D) trial compared dialysis delivered three times per week with a strategy that dialyzed only when specific metabolic or clinical triggers were met. Why this matters: AKI that progresses to dialysis is common and carries high short- and long-term risks; even modest gains in kidney recovery can change trajectories for patients and health systems. ([jamanetwork.com](https://jamanetwork.com/journals/jama/article-abstract/2841171?utm_source=openai))
Study findings at a glance
LIBERATE-D enrolled 220 adults at four U.S. academic centers who had already started kidney replacement therapy for AKI and were clinically stable. At hospital discharge, 64% of patients assigned to the conservative strategy were alive and dialysis-free for at least 14 days, compared with 50% receiving thrice-weekly dialysis. Patients in the conservative arm underwent fewer sessions (median 1.8 vs 3.1 per week) and accumulated more dialysis-free days in the first 28 days (median 21 vs 5). Episodes of dialysis-associated hypotension were also fewer with the conservative approach (69 vs 97 events). The primary end point met statistical significance in the unadjusted analysis; after prespecified adjustment, the estimate favored the conservative strategy but was not statistically significant, underscoring uncertainty in the effect size and the need for larger confirmatory trials (ClinicalTrials.gov NCT04218370). ([jamanetwork.com](https://jamanetwork.com/journals/jama/article-abstract/2841171?utm_source=openai))
What “conservative, indication-based” dialysis means
Rather than scheduling dialysis three times weekly, clinicians monitored patients and initiated treatments only when predefined thresholds were reached—such as dangerous potassium levels, severe acidosis, markedly elevated urea (blood urea nitrogen), or fluid overload causing low oxygen levels—allowing time for native kidney function to recover when safe. These trigger thresholds mirror criteria used in prior randomized trials that safely deferred starting dialysis until conventional indications developed. ([jamanetwork.com](https://jamanetwork.com/journals/jama/article-abstract/2841171?utm_source=openai))
Safety profile and physiology
Dialysis can cause sudden drops in blood pressure (intradialytic hypotension), which may diminish kidney perfusion and impede recovery. In LIBERATE-D, fewer hypotension events occurred with the conservative strategy, a finding consistent with observational data linking intradialytic hypotension to higher mortality and delayed liberation from dialysis in AKI. This provides a plausible mechanism for why “less, when safe” could support renal repair. ([jamanetwork.com](https://jamanetwork.com/journals/jama/article-abstract/2841171?utm_source=openai))
How the results fit with previous evidence
LIBERATE-D extends a decade of randomized evidence questioning the assumption that “more dialysis is better” in AKI. Large trials testing higher-intensity dosing did not improve survival and sometimes increased complications. For example, the VA/NIH ATN Trial found no mortality benefit with intensive versus less intensive renal support, and the RENAL trial reported no survival advantage with higher-effluent continuous therapy. More recently, the STARRT-AKI trial showed that accelerating the initiation of kidney replacement therapy did not reduce 90-day mortality and was associated with a higher rate of dialysis dependence among survivors. Together, these studies and the new trial suggest that tailoring dialysis to physiology and recovery—rather than fixed schedules or higher intensity—may be safer and more effective for selected patients. ([repository.niddk.nih.gov](https://repository.niddk.nih.gov/studies/atn/?utm_source=openai))
Guidelines and practice context
Most hospitals default to thrice-weekly intermittent hemodialysis for AKI, a schedule historically anchored to dose targets from earlier trials and summarized in the Kidney Disease: Improving Global Outcomes (KDIGO) 2012 guideline (for example, aiming for a weekly Kt/V of about 3.9, often delivered as 1.3 per treatment three times per week). The LIBERATE-D population, however, comprised hemodynamically stable patients already transitioning off critical illness, a group in whom preserving residual kidney function may matter as much as short-term clearance. KDIGO is updating its AKI guidance, and the new data may inform more nuanced, recovery-focused dosing for appropriate patients. ([journals.lww.com](https://journals.lww.com/CJASN/Abstract/9900/Management_of_Intermittent_Hemodialysis_in_the.4.aspx?utm_source=openai))
Expert perspective and limitations
An accompanying JAMA editorial welcomed the findings while noting statistical fragility—the unadjusted primary end point narrowly met significance, and adjusted analyses were not significant—and urged larger trials before widespread adoption. The trial’s pragmatic criteria and clear separation in dialysis exposure strengthen internal validity, but the results apply primarily to stable inpatients; effects in patients with shock, mechanical ventilation, or rapidly evolving multiorgan failure remain uncertain. ([jamanetwork.com](https://jamanetwork.com/journals/jama/articlepdf/2841172/jama_waikar_2025_ed_250085_1762194720.43049.pdf?utm_source=openai))
Who is affected
AKI affects a substantial share of hospitalized adults, and those who require dialysis face high short-term risks and long-term vulnerability to chronic kidney disease and death. According to the U.S. National Institutes of Health, hospitalization with AKI is linked to higher readmission rates and mortality after discharge, emphasizing the importance of strategies that speed kidney recovery and reduce complications. ([nih.gov](https://www.nih.gov/news-events/news-releases/being-hospitalized-acute-kidney-injury-may-increase-risk-rehospitalization-death?utm_source=openai))
Implications for care teams and health systems
For hemodynamically stable inpatients already on dialysis for AKI, adopting protocols that prioritize dialysis only when specific metabolic or clinical thresholds are met could reduce exposure to hemodialysis, lower the risk of intradialytic hypotension, and shorten time to independence from dialysis—all without evident safety trade-offs in this study. Implementation would require close laboratory and clinical monitoring, clear trigger criteria, and shared decision-making with nephrology teams. The approach is not a substitute for urgent dialysis when life-threatening derangements occur. ([jamanetwork.com](https://jamanetwork.com/journals/jama/article-abstract/2841171?utm_source=openai))
Next steps in research
Key questions include which subgroups benefit most (for example, patients with some residual urine output or improving creatinine), the safest thresholds for initiating sessions during recovery, and whether conservative strategies improve longer-term outcomes such as dialysis dependence at 90 days, quality of life, and health care utilization. Larger multicenter trials—ideally with standardized thresholds and blinded outcome adjudication—will be essential to define generalizability and refine protocols. ([jamanetwork.com](https://jamanetwork.com/journals/jama/article-abstract/2841171?utm_source=openai))
For readers seeking broader context on AKI care and policy, KDIGO’s AKI guideline resources are available here, and the STARRT-AKI trial summary from The New England Journal of Medicine outlines why initiating dialysis earlier does not necessarily improve survival or recovery. For more kidney care coverage, read more on Globally Pulse Health. ([kdigo.org](https://kdigo.org/guidelines/acute-kidney-injury/?utm_source=openai))
